Reuters logo
BRIEF-Jazz Pharmaceuticals reports psoitive data from phase 2/3 study of Xyrem
April 24, 2017 / 8:20 PM / in 8 months

BRIEF-Jazz Pharmaceuticals reports psoitive data from phase 2/3 study of Xyrem

April 24 (Reuters) - Jazz Pharmaceuticals Plc-

* Jazz Pharmaceuticals announces positive results from the phase 2/3 express study of xyrem in pediatric patients with narcolepsy with cataplexy

* Jazz Pharmaceuticals Plc - xyrem demonstrated statistically significant differences in primary and key secondary efficacy endpoints

* Jazz Pharmaceuticals - preliminary safety results consistent with results observed in xyrem studies in adults and xyrem post-marketing experience Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below